Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms

Basit Öğe Kaydı
dc.contributor.authorKarahalil, Bensu
dc.contributor.authorElkama, Aylin
dc.contributor.authorAk, Mehmet
dc.contributor.authorNemutlu, Emirhan
dc.date.accessioned2024-02-23T14:21:03Z
dc.date.available2024-02-23T14:21:03Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractOxidative stress may contribute to the development of schizophrenia and antipsychotics used in schizophrenia treatment may also cause oxidative stress. Gene polymorphisms on antioxidant and repair enzymes are responsible for individual variations and may change the efficacy of olanzapine treatment among schizophrenia patients. In our study, we assessed oxidative stress-related metabolite changes due to genetic polymorphisms on first diagnosed-schizophrenia patients treated with olanzapine. Blood samples (n = 30 patients) were taken before treatment (T1), after 10 +/- 1 days (T2), and after 3 +/- 1 months (T3). T1 served as control for T2 and T3, since it is advantageous to perform on same patient to evaluate the impact of olanzapine only. GSTs (GSTM1, GSTT1, and GSTP1) and OGG1 gene polymorphisms were analyzed by polymerase chain reaction. Changes in metabolites were detected with metabolomics profiling by gas chromatography-mass spectrometry according to each genotype before and after treatment. Multivariate analysis showed that metabolomics profiles differed after olanzapine treatment regardless gene polymorphisms. Tryptophan could be a biomarker in response to olanzapine treatment since its levels were increased after treatment. GSTM1 gene polymorphism caused significant changes in some metabolites after treatment. Urea, palmitic acid, and caprylic acid levels increased and alanine levels decreased in patients with GSTM1 null genotypes after olanzapine. In future, targeted metabolomics with these prominent metabolites and assessing gene expressions of GSTs will be beneficial to understand the mechanism of action.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey [115S229]en_US
dc.description.sponsorshipThis study was supported by The Scientific and Technological Research Council of Turkey (Grant no: 115S229).en_US
dc.identifier.doi10.1093/toxres/tfac034
dc.identifier.endpage556en_US
dc.identifier.issn2045-452X
dc.identifier.issn2045-4538
dc.identifier.issue3en_US
dc.identifier.pmid35782649en_US
dc.identifier.scopus2-s2.0-85134298577en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage547en_US
dc.identifier.urihttps://doi.org/10.1093/toxres/tfac034
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13431
dc.identifier.volume11en_US
dc.identifier.wosWOS:000804561800001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofToxicology Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOlanzapineen_US
dc.subjectMetabolomicsen_US
dc.subjectIndividual Susceptibilityen_US
dc.subjectGene Polymorphismen_US
dc.subjectGlutathione-S-Transferasesen_US
dc.titleMetabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphismsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu